WealthShield Partners LLC cut its position in ProShares S&P 500 Aristocrats ETF (BATS:NOBL – Get Rating) by 11.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,576 shares of the company’s stock after selling 6,182 shares during the quarter. ProShares S&P 500 Aristocrats ETF comprises 0.8% of WealthShield Partners LLC’s investment portfolio, making the stock its 28th biggest position. WealthShield Partners LLC’s holdings in ProShares S&P 500 Aristocrats ETF were worth $3,964,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Concord Wealth Partners lifted its stake in ProShares S&P 500 Aristocrats ETF by 209.1% in the 2nd quarter. Concord Wealth Partners now owns 340 shares of the company’s stock worth $29,000 after purchasing an additional 230 shares in the last quarter. Castle Wealth Management LLC bought a new position in shares of ProShares S&P 500 Aristocrats ETF in the 2nd quarter worth $39,000. Riggs Asset Managment Co. Inc. bought a new position in shares of ProShares S&P 500 Aristocrats ETF in the 2nd quarter worth $46,000. Twin Lakes Capital Management LLC bought a new position in shares of ProShares S&P 500 Aristocrats ETF in the 3rd quarter worth $46,000. Finally, Charter Oak Capital Management LLC bought a new position in shares of ProShares S&P 500 Aristocrats ETF in the 2nd quarter worth $51,000.
ProShares S&P 500 Aristocrats ETF Price Performance
Shares of BATS:NOBL opened at $92.09 on Wednesday. The company’s fifty day moving average price is $92.11 and its 200-day moving average price is $89.14. ProShares S&P 500 Aristocrats ETF has a one year low of $55.69 and a one year high of $67.97.
Further Reading
- Get a free copy of the StockNews.com research report on ProShares S&P 500 Aristocrats ETF (NOBL)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
Receive News & Ratings for ProShares S&P 500 Aristocrats ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares S&P 500 Aristocrats ETF and related companies with MarketBeat.com's FREE daily email newsletter.